France trials range of biosimilar incentives
Executive Summary
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.
You may also be interested in...
Lupin’s Karkaria Addresses Biosimilars Pushback
Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.
Lupin’s Karkaria On Biosimilars Pushback And Interchangeability
Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.
French Law Tackles Biologic Originator Tactics
France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
